Kyverna Therapeutics Stock Barely Moves—The Bigger CAR-T Test Is Coming
Kyverna Therapeutics shares were little changed on Wednesday after the company released updated early-stage rheumatoid arthritis data for miv-cel, its lead autoimmune cell therapy, leaving investors to weigh a broader pipeline story against the usual limits of a tiny trial. The timing matters because Kyverna is trying to show that miv-cel can be more than a single-disease bet. CAR T, or chimeric antigen receptor T-cell therapy, re-engineers immune cells to attack a target; miv-cel is an autologous therapy, meaning it is made from a patient’s own cells, and targets CD19, a marker found on B cells involved in several autoimmune diseases.